Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuta Shiraishi

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Physics in Medicine and Biology|December 12, 2024
Reply to Comments on 'Modeling for predicting survival fraction of cells after ultra-high dose rate irradiation'Yuta Shiraishi, Yusuke Matsuya, Hisanori Fukunaga
Physics in Medicine and Biology|May 3, 2024
Reply to comment on 'Modeling for predicting survival fraction of cells after ultra-high dose rate irradiation'Yuta Shiraishi, Yusuke Matsuya, Hisanori Fukunaga
Radiological Physics and Technology|January 6, 2024
Possible mechanisms and simulation modeling of FLASH radiotherapyYuta Shiraishi, Yusuke Matsuya, Hisanori Fukunaga
Physics in Medicine and Biology|December 6, 2023
Modeling for predicting survival fraction of cells after ultra-high dose rate irradiationYuta Shiraishi, Yusuke Matsuya, Tamon Kusumoto, et al.
International Journal of Molecular Sciences|September 13, 2025
Green Synthesized Titanium Oxide Nanoparticles Promote Salt Tolerance in SoybeanSetsuko Komatsu, Pwint Phoo Wai, Tatsuya Takeshita, et al.
Research and Reports in Urology|June 12, 2026
Early Progressive Disease During Nivolumab Plus Ipilimumab Therapy Predicts Poor Survival in Japanese Patients with Advanced Renal Cell Carcinoma: A Single-Center 12-Week Landmark StudyNobuki Furubayashi, Jiro Tsujita, Azusa Takayama, et al.
In Vivo (Athens, Greece)|April 28, 2026
Older Age and Outcomes of Intravesical Bacillus Calmette-Guérin for Non-muscle-invasive Bladder CancerNobuki Furubayashi, Jiro Tsujita, Azusa Takayama, et al.
Cancers|December 30, 2025
Perioperative Chemotherapy in Bladder and Upper Tract Urothelial Carcinoma: Outcomes by Nodal Status and Lymphovascular InvasionNobuki Furubayashi, Jiro Tsujita, Azusa Takayama, et al.
Cancer Diagnosis & Prognosis|March 4, 2026
Real-world Treatment Selection and Shared Decision-making in De Novo Metastatic Castration-sensitive Prostate Cancer in JapanNobuki Furubayashi, Jiro Tsujita, Azusa Takayama, et al.
Anticancer Research|April 28, 2026
Early Progressive Disease Predicts Poor Outcomes of Second-line VEGFR Tyrosine Kinase Inhibitor Therapy After First-line Nivolumab Plus Ipilimumab in Advanced Renal Cell CarcinomaNobuki Furubayashi, Jiro Tsujita, Azusa Takayama, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Physics in Medicine and Biology|December 12, 2024
Reply to Comments on 'Modeling for predicting survival fraction of cells after ultra-high dose rate irradiation'Yuta Shiraishi, Yusuke Matsuya, Hisanori Fukunaga
Physics in Medicine and Biology|May 3, 2024
Reply to comment on 'Modeling for predicting survival fraction of cells after ultra-high dose rate irradiation'Yuta Shiraishi, Yusuke Matsuya, Hisanori Fukunaga
Radiological Physics and Technology|January 6, 2024
Possible mechanisms and simulation modeling of FLASH radiotherapyYuta Shiraishi, Yusuke Matsuya, Hisanori Fukunaga
Physics in Medicine and Biology|December 6, 2023
Modeling for predicting survival fraction of cells after ultra-high dose rate irradiationYuta Shiraishi, Yusuke Matsuya, Tamon Kusumoto, et al.
International Journal of Molecular Sciences|September 13, 2025
Green Synthesized Titanium Oxide Nanoparticles Promote Salt Tolerance in SoybeanSetsuko Komatsu, Pwint Phoo Wai, Tatsuya Takeshita, et al.
Research and Reports in Urology|June 12, 2026
Early Progressive Disease During Nivolumab Plus Ipilimumab Therapy Predicts Poor Survival in Japanese Patients with Advanced Renal Cell Carcinoma: A Single-Center 12-Week Landmark StudyNobuki Furubayashi, Jiro Tsujita, Azusa Takayama, et al.
In Vivo (Athens, Greece)|April 28, 2026
Older Age and Outcomes of Intravesical Bacillus Calmette-Guérin for Non-muscle-invasive Bladder CancerNobuki Furubayashi, Jiro Tsujita, Azusa Takayama, et al.
Cancers|December 30, 2025
Perioperative Chemotherapy in Bladder and Upper Tract Urothelial Carcinoma: Outcomes by Nodal Status and Lymphovascular InvasionNobuki Furubayashi, Jiro Tsujita, Azusa Takayama, et al.
Cancer Diagnosis & Prognosis|March 4, 2026
Real-world Treatment Selection and Shared Decision-making in De Novo Metastatic Castration-sensitive Prostate Cancer in JapanNobuki Furubayashi, Jiro Tsujita, Azusa Takayama, et al.
Anticancer Research|April 28, 2026
Early Progressive Disease Predicts Poor Outcomes of Second-line VEGFR Tyrosine Kinase Inhibitor Therapy After First-line Nivolumab Plus Ipilimumab in Advanced Renal Cell CarcinomaNobuki Furubayashi, Jiro Tsujita, Azusa Takayama, et al.
Pageof 4